Vistagen Reports Positive Preliminary Phase 3 Data For Fasedienol In Social Anxiety Disorder

VistaGen Therapeutics reported preliminary positive data from the open-label extension of its Phase 3 PALISADE-3 study for fasedienol in acute social anxiety disorder. The update is directionally favorable for the drug candidate and supports the clinical program, but no detailed efficacy or safety metrics were provided. The news is likely constructive for the stock, though the immediate market impact should be limited.

Analysis

VistaGen Therapeutics reported preliminary positive data from the open-label extension of its Phase 3 PALISADE-3 study for fasedienol in acute social anxiety disorder. The update is directionally favorable for the drug candidate and supports the clinical program, but no detailed efficacy or safety metrics were provided. The news is likely constructive for the stock, though the immediate market impact should be limited.